KCM
ACAD icon

Kodai Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Kodai Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$889K Buy
+53,497
New +$972K 0.04% 138

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Kodai Capital Management's ACAD Position: Q1 2025 in Review

Kodai Capital Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2025: 53,497 shares worth $889K. The stake represents 0.04% of the portfolio and ranks #138 among its holdings.

320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

  • Kodai Capital Management held 53,497 shares of Acadia Pharmaceuticals worth $889K as of Q1 2025.
  • Acadia Pharmaceuticals was a new Kodai Capital Management position in Q1 2025.
  • Acadia Pharmaceuticals made up 0.04% of Kodai Capital Management's portfolio in Q1 2025, its #138 holding.
  • 320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Kodai Capital Management's 13F filing for Q1 2025, filed 15 May 2025.